Neurokinin antagonists as potential therapies for inflammation and rheumatoid arthritis

IDrugs

Volumn 1, Issue 1, 1998, Pages 73-91

  Von Sprecher, Andreas ^a   Gerspacher, Marc ^a   Anderson, Gary P ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001992161     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Schiff M. Emerging treatments for rheumatoid arthritis Am J Med (1997) 102(suppl 1A), 11S-15S.
2. Choy EHS, Scott DL Drug treatment of rheumatic diseases in the 1990s; achievements and future developments Drugs (1997) 23(3), 337-348.
3. Krug N, Madden J, Redington AE, Lackie P, Djukanovic R, Schauer U, Holgate ST, Frew AJ, Howarth PH. T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma. Am J Respir Cell Mol Biol (1996) 14, 319-326.
4. Larbre JP, Moore AR, Da-Silva JA, Iwamura H, Ioannou Y, Willoughby DA. Direct degradation of articular cartilage by rheumatoid synovial fluid: contribution of proteolytic enzymes. J Rheumatol (1994) 21, 1796-1801.
5. Maggi CA, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and tachikyinin receptor antagonists. J Auton Pharmacol (1993) 13, 23-93.
6. Nakanishi S. Mammalian tachykinin receptors. Ann Rev Neurosci (1991) 14, 123-136.
7. Burcher E, Mussap CJ, Stephenson JA. Autoradiographic localization of receptors in peripheral tissues In Tachykinin Receptors. Ed: Buck SH, Humana Press, Totowa, NJ (1994) 125-163.
8. Longmore J, Swain CJ, Hill RG. Neurokinin receptors. Drug News Perspec (1995) 8(1), 5-23.
9. Kucharczyk N. Tachykinin antagonists in development. Exp Opin Invest Drugs (1995) 4(4), 299-311.
10. Elliott J, Seward EM. Neurokinin receptor antagonists. Exp Opin Ther Patents (1997) 7(1), 43-54.
11. Schwab W, Bilgicyildirim A, Funk RH. Microtopography of the autonomic nerves in the rat knee: a fluroescence microscopic study. Anat Rec (1997) 247, 109-118.
12. Mapp PI. Innervation of the synovium. Ann Rheum Dis (1995) 54, 398-403.
13. Isasaki A, Ioue K, Hukuda S. Distribution of neuro-peptide-containing nerve fibers in the synovium and adjacent bone of the rat knee joint. Clin Exp Rheumatol (1995) 13, 173-178.
14. Garrett NE, Mapp PI, Cruwys SC, Kidd BL, Blake DR. Role of substance P in inflammatory arthritis. Ann Rheum Dis (1992) 51, 1014-1018.
15. Geppetti P, Bertrand C, Ricciardolo FML, Nadel JA. New aspects on the role of kinins in neurogenic inflammation. Can J Physiol Pharmacol (1995) 73, 843-847.
16. Aloe L, Probert L, Kollias G, Micera A, Tirassa P. Effect of NGF antibodies on mast-cell distribution, histamine and substance P levels in the knee joint of TNF-arthritic transgenic mice. Rheumatol Internat (1995) 14, 249-252.
17. Sluka KA, Milton MA, Willis WD, Westlund KN. Differential roles of neurokinin 1 and neurokinin 2 receptors in the development and maintenance of heat hyperalgesia Induced by acute inflammation. Br J Pharmacol (1997) 120, 1263-1273.
18. Lam FY, Wong MCS. Characterization of tachykinin receptors mediating plasma extravasation and vasodilatation in normal and acutely inflamed knee joints of the rat. Br J Pharmacol (1996) 118, 2107-2114.
19. Kidd BL, Cruwys SC, Garrett NE, Mapp PI, Jolliffe VA, Blake DR. Neurogenic influences on contralateral responses during experimental rat monoarthritis. Brain Res (1995) 688, 72-76.
20. Ahmed M, Bjurholm A, Schultzberg M, Theodorsson E, Kreicbergs A. Increased levels of substance P and calcitonin gene-related peptide in rat adjuvant arthritis. A combined immunohistochemical and radioimmuno-assay analysis. Arthritis Rheum (1995) 38, 699-709.
21. Mapp PI, Terenghi G, Walsh DA, Chen ST, Cruwys SC, Garrett N, Kidd BL, Polak JM, Blake DR. Monoarthritis in the rat knee induces bilateral and time-dependent changes in substance P and calcitonin gene-related peptide immunoreactivity in the spinal chord. Neuroscience (1993) 57, 1091-1096.
22. Bileviciute T, Lundeberg T, Ekblom A, Theodorsson E. Bilateral changes of substance P-, neurokinin A-, calcitonin gene-related peptide and neuropeptide Y-like immunoreactivity in rat knee joint synovial fluid during acute monoarthritis. Neurosci Lett (1993) 153, 37-40.
23. Sluka KA, Westlund KN. Behavioral and immunohistochemical changes in an experimental arthritis model in rats. Pain (1993) 55, 367.
24. Stucky CL, Galeazza MT, Seybold VS. Time-dependent changes in Bolton-Hunter-labeled 1251-substance P binding in rat spinal cord following unilateral adjuvant-induced peripheral inflammation. Neuroscience (1993) 57, 397-409.
25. Ahmed M, Scrinivasan GR, Theodorsson E, Schultzberg M, Kreicbergs A. Effects of surgical de-innervation on substance P and calcitonin gene-related peptide in adjuvant arthritis. Peptides (1995) 16, 569-579.
26. Garrett NE, Kidd BL, Cruwys SC, Tomlinson DR. Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of monoarthritic rats: comparison with changes in synovial substance P levels. Brain Res (1995) 675, 203-207.
27. Malcangio M, Bowery NG. Spinal cord SP release and hyperalgesia in monoarthritic rats: involvement of the GABAB receptor system. Br J Pharmacol (1994) 113, 1561-1566.
28. Hanesch U, Blecher F, Stiller VU, Emson PC, Schaible HG, Heppelmann B. The effect of a unilateral inflammation at the rat's ankle joint on the expression of preprotachykinin-A mRNA and preprosomatostatis mRNA in dorsal root ganglion cells - a study using non-radioactive in situ hybridization. Brain Res (1995) 700, 279-284.
29. Menkes CJ, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoparthritis. J Rheumatol (1993) 20, 714-717.
30. Hemanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Amalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol (1993) 32, 31-35.
31. Amalich F, de Miguel E, Perez-Ayala C, Martinez M, Vazquez JJ, Gijon-Banos J, Hernanz A. Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations. Neurosci Lett (1994) 170, 251-254.
32. Anichini M, Cesaretti S, Lepori M, Maddali Bongi S, Maresca M, Zoppi M. La substance P dans la serum des patients atteints de polyarthrite rheumatoide. Rev Rheum [Ed Fr] (1997) 64(1), 19-22.
33. Sacerdote P, Carrabba M, Galante A, Pisati R, Manfredi B, Panerai AE. Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients effect of the nonsteroidal anti-inflammatory drugs idomethacin, diclofenac and naproxen. Infl Res (1995) 44, 486-490.
34. De Miguel E, Amalich F, Tato E, Vazquez JJ, Gijon-Banos J, Hernanz A. The effect of gold salts on substance P level in rheumatoid arthritis. Neurosci Lett (1994) 174, 185-187.
35. Bileviciute I, Lundeberg T, Ekblom A, Theodorsson E. Substance P-, neurokinin R-, calcitonin gene-related peptide and neuropeptide Y-like immunoreactivity (-II) in rat knee joint synovial fluid during acute monoarthritis is not correlated with concentrations of neuropeptide-LI in cerebrospinal fluid and plasma. Neurosci Lett (1994) 167, 145-148.
36. Kar S, Rees RG, Quirion R. Altered calcitonin gene-related peptide, substance P and enkephalin immuno-reactivities and receptor binding sites in the dorsal spinal cord of the polyarthritic rat. Eur J Neurosci (1994) 6, 345-354.
37. Calvino B, Couraud JY, Besson JM. Prevaccination with diluted Freund adjuvant prevents the development of chronic pain and transient release of cerebrospinal fluid substance P in adjuvant-induced arthritis in rats. Pain (1994) 58, 211-217.
38. Krause JE, DiMaggio DA, McCarson KE. Alternations in neurokinin 1 receptor gene expression in models of pain and inflammation. Can J Physiol Pharmacol (1995) 73, 854-859.
39. Malcangio M, Bowery NG. Calcitonin gene-related peptide content, basal outflow and electrically-evoked release from monoarthritic rat spinal cord in vitro. Pain (1996) 66, 351-358.
40. Neugebauer V, Weiretter F, Schaible HG. Involvement of substance P and neurokinin-1 receptors in the hyperexcitability of dorsal horn neurons during development of acute arthritis in rat's knee joint. J Neurophysiol (1995) 73, 1574-1583.
41. Neugebauer V, Rumenapp P, Schaible HG. Mechanisms of oxyradical production in substance P stimulated rheumatoid synovial cells. Rheumatol Int (1996) 16, 159-167.
42. Tanabe T, Otani H, Mishima K, Ogawa R, Inagaki C. The role of spinal neurokinin-2 receptors in the processing of nociceptive information from the joint and in the generation and maintenance of inflammation-evoked hyperexcitability of dorsal horn neurons in the rat. Eur J Neurosci (1996) 8, 249-60.
43. Rameshwar P, Ganea D, Gascon P. Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-1 and IL-6. J Immunol (1994) 152, 4044-4054.
44. Bileviciute I, Rheodorsson E, Lundberg T. Is the pretreatment effect of low dose Freund's adjuvant on adjuvant arthritis due to an activation of the nervous system? Neuropeptides (1996) 30, 405-411.
45. a) Carleson J, Alstergren P, Appelgren A, Applegren B, Kopp S, Theodorsson E, Lundeberg T. A model for the study of experimentally induced temporamandibular arthritis in rats: the effect of human recombinant interleukin-1α on neuropeptide-like immunoreactivity. J Orofacial Pain (1996) 10, 9-14.
46. b) Carleson J, Alstergren P, Appelgren A, Applegren B, Kopp S, Srinivasan GR, Theodorsson E, Lundeberg T. Effects of adjuvant on neuropeptide-like immunoreactivity in experimentally induced temporomandibular arthritis in rats. Arch Oral-Biol (1996) 41, 705-712.
47. Jeanjean AP, Moussaoui SM, Maloteaux JM, Laduron PM. Interleukin-1 beta induces long-term increase of axonally transported opiate receptors and substance P. Neuroscience (1995) 68, 151-157.
48. Lowe,III JA, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, Jackson ER, McLean S, Bryce DK, Bordner J, Nagahisa A, Kanai Y, Suga O, Tsuchiya M. The discovery of (2S,3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)-methyl]-1-azabicyclo[2.2.2]- octan-3-amine as novel, non-peptide Substance P antagonist. J Med Chem (1992) 35, 2591-2600.
49. Regoli D, Boudon A, Fauchére JL Receptors and antagonists for Substance P and related peptides. Pharmacol Rev (1994) 46(4), 551-599.
50. 1 tachykinin receptor. Med Res Rev (1996) 16(4), 297-317.
51. Lowe,III JA. Nonpeptide tachykinin antagonists: medicinal chemistry and molecular biology. Med Res Rev (1996) 16(6), 527-545.
52. Desai MC, Lefkowitz SL, Thadeio PF, Longo KP, Snider RM. Discovery of a potent Substance P antagonist: recognition of the key molecular determinant. J Med Chem (1992) 35, 4911-4913.
53. 1 receptor. J Pharmacol Exp Ther (1996) 277, 900-908.
54. 1 antagonists 2: investigation of the effect of N-substitution. Bioorg Med Chem Lett (1995) 5(3), 209-212.
55. 2+) immobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol (1996) 317(1), 129-135.
56. 1 antagonists. J Med Chem (1992) 39(15), 2907-2914.
57. Hale JJ, Mills SG, MacCoss M, Shah SK, Qi H, Mathre DJ, Cascieri MA, Sadowski S, Strader CD, MacIntyre DE, Metzger JM. 2(S)-((3,5-Bis(trifluormethyl)benzyl)-oxy-3(S)-phenyl-4-((3-oxo-1,2,4-triazol-5- yl)methylmorpnoline (1): A potent orally active, morpholine-based human neuro-kinin-1 receptor antagonist. J Med Chem (1996) 39(9), 1760-1762.
58. 1 antagonists. Tachykinins in Health and Disease (September 7-11, 1997), Cairns, Australia, Abstract book p 4.
59. Newby DE, Sciberras DG, Ferro CJ, Mendel CM, Gertz BJ, Lowry RC, Webb DJ. Antagonism of Substance P-induced forearm vasodilatation by the neurokinin type 1 receptor antagonist, L-758,298. Proc Br Pharmacol Soc (September 2-4, 1997), Edinburgh, UK, Abstract C110.
60. 1 receptor antagonist. Br J Pharmacol (1995) 116(8), 3149-3157.
61. 1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl) (2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. J Med Chem (1996) 38(26), 4985-4992.
62. 1 receptor antagonists: the identification of an exceptionally potent orally active antiemetic compound. Bioorg Med Chem Lett (1996) 6(9), 1015-1020.
63. Alfieri AB, Gardner CJ, Twissell DJ. Dexamethasone enhances GR205171 inhibition of cytotoxic-induced plasma protein extravasation in ferrets. Br J Pharmacol (1996) 118 (Proc Suppl)), 151P.
64. Fardin V, Foucault F, Bock MD, Garret C. Binding profile of RP-67580, a new non-peptide SP antagonist: comparison with CP 96,345. Br J Pharmacol (1992) 105, 80.
65. 1 antagonists: the triarylperhydroisoindolois. Bioorg Med Chem Lett (1994) 4(5), 673-676.
66. 1 receptor. Can J Physiol Pharmacol (1994) 72(Suppl.1), 459.
67. 2 tachykinin receptor specificities of perhydroisoindoles. 25th Ann Meeting Soc Neurosci, San Diego CA, November 11-16, 1995, 402.6.
68. 1 antagonists. 25th Nat Med Chem Symp, Ann Arbor, Michigan USA, June 18-22, 1996, 84.
69. Fujii T. Discovery and pharmacological properties of selective neurokinin-receptor antagonists, FK-224 and FK-888. Folia Pharmacol Jpn (1995) 106(3), 193-204.
70. Hirayama Y, Lei Y-H, Barnes PJ, Rogers DF. Effects of two novel tachykinin antagonists, FK-224 and FK-888, on neurogenic airway plasma exudation, bronchoconstriction and systemic hypotension in guinea pigs in vivo. Br J Pharmacol (1993) 108, 844-851.
71. Walpole CSJ, Ko SY, Brown M, Beattie D, Campbell E, Dickenson F, Ewan S, Gentry C, Hughes GA, Lerpiniere J, Patel S, Urban L. SDZ NKT 343- A potent human NK-1 receptor antagonist with good oral analgesic activity in chronic pain models. Tachykinins in Health and Disease (September 7-11, 1997), Cairns, Australia, Abstract book p 4.
72. Walpole C, Ko SY. New pyrrolidine derivatives are tachykinin antagonists- useful as analgesics and as anti-inflammatory and antiemetic agents. World (PCT) Patent WO-9618643 (1996).
73. 1 receptor. Br J Pharmacol (1997) 120(Proc. Suppl.), abstract 202P.
74. Swain, CJ. Neurokinin receptor antagonists. Exp Opin Ther Patents (1996) 6(4), 367-378.
75. Astolfi M, Goso C, Maggi M, Manzini S. Binding profile of a potent and selective antagonist of NK-1 tachykinin receptors: MEN 10930. Tachykinins '95 Florence (October 16-18, 1995), Abstract book, 118.
76. 1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523. Eur J Pharmacol (1996) 310(1), 37-46.
77. Fauchere J-L, Kucharczyk N, Jacoby E, Lonchampt M, Robinau P, Dacquet C, Regoli D, Canet E. The dipeptide neurokinin-1 receptor antagonist S19752 is a potent and long-acting inhibitor of bronchoconstriction when administered by aerosol to the guinea pig in vivo. Bioorg Med Chem Lett (1997) 7(2), 203-208.
78. 1 receptor antagonists. Bioorg Med Chem (1994) 2(5), 357-370.
79. 1 receptor antagonist. Eur J Pharmacol (1993) 250, 403-413.
80. 1 receptor antagonist SR 140,333 produces long-lasting inhibition of neurogenic inflammation, but does not influence acute chemo- or thermonociception in rats. Arch Pharmacol (1995) 352(2), 201-205.
81. Hipskind PA, Howbert JJ, Bruns RF, Cho SSY, Crowell TA, Foreman MM, Gehlert DR, Iyengar S, Johnson KW, Krushinski JH, Li DL, Lobb, KL, Mason NR, Muehl BS, Nixon JA, Phebus LA, Regoli D, Simmons RM, Threlkeld PG, Waters DC, Gitter BD. 3-Aryl-1,2-diacetamidopro-pane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem (1996) 39(3), 736-748.
82. Goldstein D. Clinical trials with lanepitant. William Harvey Res Inst Conf Tachykinins and their antagonists (October 10-11, 1996), London.
83. Iyengar S, Hipskind PA, Gehlert DR, Schober D, Gitter BD, McMillian C, Couture R, Li D, Simmons RMA. LY303870: a centrally active NK-1 antagonist with a long duration of action. Tachykinins '95 Florence (October 16-18, 1995), Abstract book, 122.
84. Natsugari H, Ikeura Y, Kiyota Y, Ishichi Y, Ishimaru T, Saga O, Shirafuji H, Tanaka T, Kamo I, Doi T, Otsuka M. Novel, potent, and orally active Substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine. J Med Chem (1995) 38(16), 3106-3120.
85. 1 antagonists derived from L-tryptophan. J Med Chem (1995) 38(6), 934-941.
86. 1 antagonist. Bioorg Med Chem Lett (1996) 6(14), 1623-1628.
87. 2 receptor. Drugs Future (1995) 20(7), 701-707.
88. 2 receptor antagonist SR 48968 on neurokinin A-induced broncho-constriction in asthmatics. Eur Resp J (1996) 9(Suppl. 23), 289S.
89. 1 receptor antagonist. Biochemical and pharmacological activities Tachykinins in Health and Disease (September 7-11, 1997), Cairns, Australia, 5.
90. Kubota H, Kakefuda A, Nagaoka H, Yamamoto O, Ikeda K, Shibanuma T, Isomura Y. Spiro-substituted piperidines: potent and selective neurokinin A antagonists. AFMC Int Med Chem Symp/AIMECS 95, Tokyo, Japan (September 3-8, 1995) M139.
91. 2 antagonist ZD-7944. 214th ACS National Meeting, Las Vegas, NV September 7-11 (1997), MEDI 264.
92. Jacobs RT. 4-(Aryl-substituted)-piperidines as neurokinin receptor antagonists. Eur Pat Appl EP630887 (1994).
93. 2 receptors. J Pharmacol Exp Ther (1994) 271, 1489-1500.
94. 2 receptor antagonist, in guinea pig airways. Eur J Pharmacol (1995) 273, 129-135.
95. 2 receptor antagonists. Bioorg Med Chem Lett (1994) 4(16), 1951-1956.
96. Howson W. Rational design of tachykinin receptor antagonists. Drug News and Perspectives (1995) 8(2), 97-103.
97. 2 tachykinin receptor ligands. Br J Pharmacol (1993) 110 (Suppl.), 56P.
98. Aharony D, Buckner CK, Ellis JL, Ghanekar SV, Graham A, Kays JS, Little J, Meeker S, Miller SC, Undem BJ, Waldron IR. Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity. J Pharmacol Exp Ther (1995) 274, 1216-1221.
99. Lunde H, Hedner J, Svedmyr N. Lack of efficacy of 4 weeks treatment with the neurokinin receptor antagonist FK224 in mild to moderate asthma. Eur Resp J (1994) 7(Suppl. 18), 151S.
100. 2 dual antagonist) on the knee joint inflammation induced by carrageenin, substance P, serotonin and antigen. Regul Pep (1992), Suppl 1, Abst. S59.
101. 2 receptors. Bioorg Med Chem Lett (1996) 6(8), 951-956.
102. Kudlacz EM, Scott A, Shatzer SA, Knippenberg RW, Logan DE, Poirot M, van Giersbergen PLM, Burkholder TP. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist. J Pharmacol Exp Ther (1996) 277, 840-851.
103. Kudlacz EM, Knippenberg RW, Shatzer SA, Kehne JH, McCloskey TC, Burkholder TP. The peripheral NK-1/NK-2 receptor antagonist MDL-105172A inhibits tachykinin-mediated respiratory effects in guinea pigs. J Auton Pharmacol (1997) 17(2), 109-119.
104. 2 receptors. 212th ACS National Meeting, Orlando, Florida, USA, August 25-29, (1996), MEDI 136.
105. Mills, SG et al. William Harvey Res Inst Conf Tachykinins and their antagonists (October 10-11, 1996), London, P5.
106. 2 receptor antagonist. Eur J Pharmacol (1995) 294, 677-684.
107. 3 receptor. Life Sci (1995) 56(1), PL27-32.
108. 3 receptor selective antagonists. Bioorg Med Chem Lett (1995) 5(16), 1773-1778.
109. Giardina GAM, Sarau HM, Farina C, Medhurst AD, Grugni M, Foley JJ, Raveglia LF, Schmidt DB, Rigolio R, Vassallo M, Vecchietti V, Hay DWP. 2-Phenyl-4-quinoline-carboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor. J Med Chem (1996) 39(12), 2281-2284.
110. Cairns, Australia, Abstract book p 5.
111. 2 receptor antagonist. Br J Pharmacol (1998) 123, 81-91.